Enveric Biosciences, Inc. Common Stock
Compare this stock
ENVB Stock Report Card
$
38%
Performance
Score:
10/100
ENVB returned -58.09% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
14/100
ENVB receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
Score:
100/100
ENVB has missed earnings 1 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, ENVB has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
64/100
ENVB has had a higher than average amount of volatility over the last 12 months giving it a score of 64 of 100.
Enveric Biosciences, Inc. Common Stock Summary
Nasdaq / ENVB
Healthcare
Biotechnology
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
ENVB scored poorly on our reportcard. Here are some similar companies and how they performed.
